Executive Director Bioanalysis Bristol-Myers Squibb Company LAWRENCEVILLE, New Jersey, United States
The biologics development has evolved in past decade with the development of multiple domain specificities, conjugated biologics with small molecules, small peptides, nucleic acids, cell and viral vector-based gene therapies. All of these advances have provided new options for treatment of untreatable diseases like oncology, autoimmunity, rare diseases with gene-defects and neurological disorders. These advanced modalities require a better understanding of risks associated at each stage of preclinical development and tools to support translational development.
